Takeda reported the latest results of mobocertinib, further confirming the clinical benefits of patients with EGFR exon 20 insertion + mNSCLC

−This result shows that the median overall survival of the oral targeted therapy drug mobocertinib is 24 months, and a variety of EGFR exon 20 (Exon20) insertion variants all have remissions

TSE:4502/NYSE:TAK NSCLC video

Suresh S.

The analysis from the Phase 1/2 trial included patients with EGFR exon 20 insertion + mNSCLC who had previously received platinum-containing chemotherapy.

International Society for Lung Cancer Research (IASLC) 2020 World Conference on Lung Cancer (WCLC)

The measured safety is manageable and consistent with previous findings.

Dr.

mobocertinib previously passed the FDA Breakthrough Therapy Certification in April 2020, and entered the New Drug Application (NDA) priority review in April 2021.

Takeda has set up the Expansion Access Point (EAP), and patients may be eligible for mobocertinib during the regulatory approval of the drug under development.

Here

Please learn more about the layout of Takeda Oncology at this year's ASCO annual meeting .

Learn more about Takeda's Oncology Department's layout at this year's ASCO annual meeting.

About the Phase 1/2 trial

About the Phase 1/2 trial

This phase 1/2 trial evaluates the safety, pharmacokinetics, and anti-tumor activity of oral mobocertinib in patients with non-small cell lung cancer (NSCLC).

The previous population effectiveness analysis of platinum-containing treatment investigated 114 patients with EGFR exon 20 insertion + mNSCLC who received platinum-containing treatment and received mobocertinib 160 mg once daily in this phase 1/2 trial.

About EGFR exon 20 insertion + mNSCLC

About EGFR exon 20 insertion + mNSCLC

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.

Diagnosis ^{1,2 3-7}

Takeda is committed to continuing EGFR exon 20 insertion + mNSCLC the field of research and development, with a view to approximately 30,000 cases worldwide (including the United States alone, 3,000 cases) patients were diagnosed of the disease each year to provide a targeted treatment options ^3,4 .

^3,4

Takeda's commitment to oncology

Takeda's commitment to oncology

Our core research and development mission is to deliver new drugs to cancer patients around the world through our commitment to science, breakthrough innovation, and passion for improving the lives of patients.

Takeda Pharmaceutical Co.

TSE: 4502/NYSE: TAK https:// hintimportant hint

For the purposes of this article, "press release" refers to this document, any oral statement, any question-and-answer session, and any written or oral materials discussed or distributed by Takeda Pharmaceutical Co.

Companies directly or indirectly held by Takeda through investment are independent entities.
In this press release, sometimes for convenience, "Takeda" is used as a collective term for Takeda and its subsidiaries.
Similarly, words like "we" (subject and object forms) and "our" are also collective names for subsidiaries or represent employees of the company.
These expressions are also used in situations that have no practical meaning and do not involve a particular company or certain companies.

Forward-looking statements

Forward-looking statements

This press release and any materials distributed in connection with it may contain forward-looking statements, views or opinions related to Takeda’s future business, future conditions and operating performance, including Takeda’s estimates, forecasts, goals and plans.
Forward-looking statements often include but are not limited to the following words, such as "target", "plan", "believe", "hope", "continue", "anticipate", "intend", "intend", "ensure", " "Will", "may", "should", "will", "maybe", "expect", "estimate", "forecast" or similar expressions or their negative form.
These forward-looking statements are based on assumptions about many important factors, including the following factors, which may cause actual results to differ materially from those expressed or implied by the forward-looking statements: The economic situation faced by Takeda’s global operations, including Japan and the United States The macroeconomic environment; competitive pressures and developments; changes in applicable laws and regulations; including global medical reforms; inherent challenges in the development of new products, including the uncertainty of clinical success and the timing of decisions or decision-making by regulatory authorities; new products And uncertainty about the commercial success of existing products; manufacturing difficulties or delays; fluctuations in interest rates and exchange rates; claims or questions about the safety or efficacy of sold products or candidate products; health crises such as the new coronavirus pandemic affect Takeda and The impact of its customers and suppliers, including foreign governments in the country in which Takeda operates or other aspects of its business; the timing and impact of post-merger integration efforts of acquired companies; whether it is possible to divest non-core assets of Takeda’s operations and any such Timing of the divestiture; and other factors described in the latest Form 20-F annual report and other reports submitted by Takeda to the US Securities and Exchange Commission.
For details, please refer to the Takeda website https:// Or.
Takeda does not undertake to update any forward-looking statements in this press release or any other forward-looking statements that the company may issue, unless required by law or securities trading rules.
Historical performance does not represent future performance, and the performance or statement of Takeda in this press release cannot be referred to, nor is it an estimate, forecast, guarantee or conjecture of Takeda’s future performance.

https://informationMedical information

The products mentioned in this press release may not be on the market in all countries, or may be sold under different trademarks, or used for different diseases, or in different dosages, or have different effects.
Any information contained in this article should not be regarded as an application, promotion or advertisement of any prescription drugs, including those drugs under development.

Leave a message here